International Journal of Polymeric Materials · مجلد 75 (8) · 835-858
Folate-conjugated chitosan nanoparticles represent a promising advancement in targeted drug delivery, offering enhanced specificity, biocompatibility, and controlled release profiles. Chitosan, a versatile biopolymer, provides a stable platform for nanoparticle synthesis, while folate conjugation enables selective targeting of folate receptors, which are overexpressed in various cancers and inflammatory diseases. This review explores the structural and functional properties of chitosan, mechanisms of folate receptor-mediated endocytosis, and innovative strategies for nanoparticle synthesis and functionalization. The review entails key formulation techniques, including nanoprecipitation, ionic gelation, and spray drying, alongside characterization methods essential for optimizing therapeutic efficacy. The biomedical applications of Folate-conjugated chitosan nanoparticles are highlighted in cancer therapy, gene delivery, and anti-inflammatory treatments, with an emphasis on emerging trends such as CRISPR-based targeting and dual-ligand strategies. This review critically examines the existing challenges and explores future directions, highlighting the promising role of folate-conjugated chitosan nanoparticles in the evolution of precision medicine.
targeted drug deliveryfolate receptorreceptor-mediated endocytosisnanoprecipitation
The advent of CRISPR‒Cas technology has revolutionized genome editing by providing unprecedented precision, efficiency, and versatility in genetic manipulation. This revolutionary system originated from bacterial adaptive immunity. It allows the programmed modification of DNA sequences in a highly specific way, as long as the desired modification site contains an enzyme-compatible protospacer adjacent motif (PAM) sequence. Recent innovations with CRISPR‒Cas systems have focused on optimizing delivery methods, addressing challenges and expanding their therapeutic applications. Delivery approaches, including viral vectors, lipid nanoparticles, and other nonviral vectors, have been improved to increase target specificity while minimizing off-target effects, ensuring safe and efficient In Vivo genome editing. The applications of CRISPR‒Cas technology include the correction of genetic disorders, engineering of immune cells for cancer therapy, and combating viral infections. However, significant challenges in the form of unintended edits, immune responses, and delivery to specific tissues or organs remain formidable barriers to clinical translation. New CRISPR variants, such as base editing, prime editing, and epigenome editing, provide solutions to improve accuracy and broaden intervention. This review covers recent progress in various CRISPR delivery methodologies, discusses broadening therapeutic applications, highlights ongoing challenges, and describes the future trajectory of this disruptive technology.
Background/Objectives: Repurposing existing drugs may represent a promising strategy for effective cancer therapy. This study was the first to investigate the augmented antitumor therapeutic effect achieved by co-incorporating the NSAID Niflumic acid (NIF) with ceramides into PEGylated cerosomes (NIF-loaded PEG-CERs) in a novel platform that targets specifically the MAPK-ERK signaling pathway and miR-21-5p modulation. Methods: The prepared formulae were statistically optimized utilizing a full factorial design and the optimal formula (C5) was further incorporated into a topical gel and evaluated for ex vivo rat skin permeation, and tested in vivo in a subcutaneous solid Ehrlich carcinoma (SEC) mice model. Results: The optimal formula (C5) showed tubular elongated morphology with higher EE% (96.71 ± 0.0), lower vesicular size (VS) and PDI values, 292.95 ± 0.78 nm and 0.47 ± 0.0 respectively. A high ZP value (−37.5 ± 0.57 mV) was in accordance with stability results showing good stability of the optimal formula (C5). Permeability studies exhibited 2.02-fold higher skin permeation compared to pure NIF gel. A significant decrease in tumor volume and marked improvement in survival rate in SEC mice were confirmed by downregulation of EGFR, ERK1, ERK2, and miR-21-5p expression. Furthermore, an increase in total antioxidant capacity and caspase-3 levels was observed, accompanied by significant suppression in cyclin D1, MMP-2, COX-2, and MDA levels. Finally, histopathological analysis revealed the superior antitumor effect of C5 gel together with immunohistochemical assay showing the lowest BCL-2-positive staining, indicating the restoration of physiological apoptotic balance. Conclusions: Based on the previous findings, NIF-loaded PEG-CERs offer augmented therapeutic potential for efficient topical skin cancer management in an SEC mice model.
Journal of Computational Biophysics and Chemistry · 1-20
The development of selective vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors remains a promising strategy for anticancer therapy targeting tumor angiogenesis. In the study at hand, a novel benzanilide-based derivative, ACEB-Cl, was rationally designed by assimilating fundamental pharmacophoric characteristics essential for VEGFR-2 inhibition. ACEB-Cl was evaluated using a comprehensive approach that combined computational modeling, synthesis, and in vitro biological assessment. Density functional theory (DFT) calculations revealed a favorable electronic profile, with distinct nucleophilic and electrophilic regions that could support potential interactions within the VEGFR-2 binding pocket. Docking and molecular dynamics (MD) simulations suggested stable binding of ACEB-Cl within the ATP-binding pocket, supported by strong hydrophobic interactions and favorable binding free energy ([Formula: see text] kcal/mol). Following synthesis, ACEB-Cl confirmed potent anti-VEGFR-2 activity in an ELISA-based assay (IC[Formula: see text]M), showing higher potency than sorafenib. Western blot analysis further confirmed significant downregulation of phosphorylated VEGFR-2 in MDA-MB-231 cells. In vitro cytotoxicity studies revealed selective anticancer activity, with reduced toxicity toward normal Vero cells and favorable selectivity indices. Mechanistically, ACEB-Cl triggered G0/G1 phase arrest and significantly increased apoptotic cell death, highlighting its ability to suppress cancer cell proliferation. Additionally, ADMET and toxicity estimations indicated a balanced pharmacokinetic and safety profile, with improved solubility, acceptable absorption, and reduced toxicity risks compared to sorafenib. Overall, this integrated study pinpointed ACEB-Cl as a promising VEGFR-2-targeted anticancer lead compound with strong inhibitory potency and a clearly defined mechanism of action, supporting its progression for further improvement.
VEGFR-2 inhibitorsbenzanilidestumor angiogenesisanticancer drug discovery
The continuous progression of cancerous severity due to the interaction of physical (ultraviolet radiation), chemical (smoking, mycotoxins, and heavy metals), and biological (microbial populations) carcinogens inspired scientists to develop a correlation between active therapeutic agents and cancer proliferation. This review highlights the molecular mechanism by which lycopene imparts its anticancerous role, focusing on clinical and animal trials to validate its effectiveness. The antioxidant profile of lycopene promotes anticancerous properties that reduce cancer prevalence by activating cell signaling pathways and gene expression (involved in cancer cell proliferation). Lycopene's anti-inflammatory properties suppresses the tumor growth and development-promoting pathways, such as the PI3K/Akt/mTOR pathway. The anticancer property of lycopene is also evidenced by its inhibitory potential of the Wnt/β-catenin signaling pathway that is involved in cancer cell modulation and propagation. Lycopene also suppresses and neutralizes oxidative stress and reactive oxygen species (ROS)-induced DNA damage, preventing gene mutation. Inflammation-induced cell death is mitigated by lycopene's anti-inflammatory potential that lowers the expression of interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Several clinical and randomized control trials have revealed the effect of lycopene supplementation in the management of cancer, including breast cancer, pancreatic cancer, prostate cancer, colon cancer, ovarian cancer, skin cancer, oral cancer, liver cancer, gastric cancer, and kidney cancer, by lessening prostate-specific antigen (PSA) levels. These studies also accentuate certain limitations that need further trials to evaluate the long-term consequences of lycopene supplementations and their specific effective dose.
Frontiers in Pharmacology · مجلد 16 · 1595177-1595177
Background Albendazole (ALB), originally developed as an anthelmintic agent, has been repurposed for use in cancer therapy. In the present work, ALB was incorporated into stearyl amine (SA)-based elastic cerosomes (EC) to improve its anticancer activity. Methods Stearyl amine elastic cerosomes containing albendazole (SA-EC-ALB) were formulated using the thin-film hydration method. A D-optimal experimental design was applied via Design-Expert® software (version 7) generating 19 formulations. The independent variables included SAA amount (X1), sonication time (X2), ceramide type (X3), and SAA type (X4), while the dependent variables were entrapment efficiency (EE%; Y1), particle size (PS; Y2), and polydispersity index (PDI; Y3). Results The optimized SA-EC-ALB formulation, prepared with ceramide III and Pluronic L121 through sonication, achieved an entrapment efficiency (EE%) of 92.03 ± 3.53% and a particle size (PS) of 312.05 ± 9.32 nm. In-silico analysis indicated strong interactions between ALB and the vesicular components in water. Moreover, in-vivo evaluation of SA-EC-ALB antitumor activity, performed using the solid Ehrlich tumor model in adult Swiss albino male mice, demonstrated a significant reduction in tumor volume compared to the control group. Conclusion Loading ALB into SA-EC could potentially induce its anticancer effects.
BACKGROUND: Topoisomerase II (Topo II) remains a validated target for anticancer therapy, with many clinically used agents acting via DNA intercalation and enzyme inhibition. However, their clinical use is limited by severe toxicity and resistance. In this study, we investigate aotaphenazine, a rare hydrophenazine derivative isolated from Streptomyces sp. IFM 11694 as a potential novel Topo II inhibitor with selective anticancer activity. METHODS: Molecular docking and 400 ns molecular dynamics (MD) simulations were employed to evaluate aotaphenazine's binding mode within the DNA-Topo II complex (PDB: 3QX3). MM-GBSA calculations quantified interaction energetics, while ProLIF and PLIP analyses detailed the interaction patterns. Topo II inhibition was assessed via in vitro enzymatic assays. Cytotoxicity (MTT) assays were conducted against a panel of human cancer and normal cell lines. Flow cytometry was used to evaluate apoptosis and cell cycle progression in MDA-MB-231 cells. RESULTS: aotaphenazine demonstrated a docking binding energy of -19.12 kcal/mol and remained stably intercalated within the DNA groove during MD simulations. MM-GBSA analysis showed a total binding free energy of -29.81 kcal/mol, driven primarily by van der Waals forces. Interaction profiling identified consistent π-stacking with Cyt8 and Thy9, and strong binding contributions from Ade12 and Gua13. Enzymatic assays confirmed Topo II inhibition with an IC50 of 45.01 nM, comparable to doxorubicin (30.16 nM). In vitro cytotoxicity analysis revealed moderate activity across cancer cell lines (IC50 = 26.30-54.35 µM) and significantly reduced toxicity in normal WI-38 and WISH cells (IC50 = 69.86 µM and 84.72 µM, respectively). Flow cytometry showed that aotaphenazine induced early (20.98%) and late apoptosis (42.80%), along with S-phase cell cycle arrest (43.99%) and a marked reduction in the G2/M population in MDA-MB-231 cells. CONCLUSION: aotaphenazine exhibits a compelling combination of Topo II inhibition, DNA intercalation, and selective anticancer activity, supported by both computational modeling and biological validation. Its lower cytotoxicity toward normal cells and ability to induce apoptosis and cell cycle arrest suggest strong therapeutic potential. These findings establish aotaphenazine as a promising lead compound for the development of safer and more selective Topo II-targeting anticancer agents.
topoisomerase II inhibitionDNA intercalationanticancer activitynatural product isolation
INTRODUCTION: Epidermal Growth Factor Receptor (EGFR) is a well-established therapeutic target in cancer treatment. In this study, a novel N-phenylacetamide derivative of theobromine, designated as T-1-PA, was designed as a potential semisynthetic EGFR inhibitor. METHOD: The 3D structure, stability, and electronic reactivity of T-1-PA were determined using Density Functional Theory (DFT) analyses. Molecular docking, molecular dynamics (MD) simulations, Molecular Mechanics Generalized Born Surface Area (MM-GBSA), Protein-Ligand Interaction Profiler (PLIP), and Principal Component Analysis of Trajectories (PCAT) were employed to evaluate the binding affinity and inhibitory potential of T-1-PA against EGFR. Computational ADMET profiling was conducted to predict drug-likeness and safety. Subsequently, T-1-PA was semisynthesized and subjected to in vitro biological evaluation. RESULTS: Computational analyses demonstrated a strong binding affinity of T-1-PA to EGFR. The compound exhibited favorable ADMET properties. In vitro assays revealed potent EGFR inhibition with an IC₅₀ of 0.736 ± 0.005 μM. T-1-PA also inhibited the proliferation of HepG2 and MCF7 cancer cell lines with IC₅₀ values of 0.88 ± 0.01 μM and 1.13 ± 0.01 μM, respectively. Flow cytometry analysis indicated induction of apoptosis and G1 phase cell cycle arrest in HepG2 cells. Additionally, T-1-PA significantly impaired HepG2 cell migration and wound-healing capacity. DISCUSSION: The results validate the computational predictions and highlight the anticancer potential of T-1-PA through EGFR inhibition and antiproliferative activity. The compound's favorable pharmacokinetic and safety profiles further support its therapeutic promise. CONCLUSION: T-1-PA is a promising semisynthetic compound with selective antiproliferative activity mediated via EGFR inhibition. These findings encourage further preclinical investigation of T-1-PA as a novel candidate for EGFR-targeted cancer therapy.
A novel sulfamoylphenyl-dihydro-thiadiazole derivative (compound 14) has been designed and synthesized as a dual inhibitor targeting EGFR and human carbonic anhydrases (hCA_IX and hCA_XII). Computational studies, including density functional theory (DFT), molecular docking, and molecular dynamics simulations, confirmed its stability, favorable binding interactions, and reactivity profiles. Compound 14 showed potent inhibition of EGFR (IC₅₀ = 10.12 ± 0.29 nM), hCA_IX and hCA_XII (IC₅₀ = 79 ± 1.2 nM and 58 ± 0.9 nM, respectively). Cytotoxicity assays demonstrated selective activity against cancer cells, with IC₅₀ values of 16.13 µM in MDA-MB-231 and 22.57 µM in MCF-7 cells, compared to 148.32 µM in non-cancerous Vero cells. Compared to acetazolamide, compound 14 exhibited improved selectivity for cancer cells. Apoptosis studies revealed significant cell death in MDA-MB-231 cells, with early and late apoptosis rates of 22.50% and 58.27%, respectively, alongside a marked G1-phase cell cycle arrest (49.10% in treated cells vs. 44.98% in controls). In silico toxicological evaluations indicated a favorable safety profile, with low irritancy and acceptable rat oral LD₅₀ (15.81 mg/kg) and carcinogenic potency (TD₅₀ = 36.95). Compound 14's potent dual inhibition and selective cytotoxicity make it a promising candidate for further optimization and in vivo studies.
BACKGROUND: Vascular endothelial growth factor receptor-2 (VEGFR-2) is a validated target in cancer therapy. However, approved inhibitors like sorafenib are often limited by off-target toxicity and resistance. This study aimed to develop novel thiadiazole-based VEGFR-2 inhibitors with improved selectivity and safer profiles. METHODS: A series of 2,3-dihydro-1,3,4-thiadiazole derivatives was rationally designed, synthesized, and structurally characterized. In vitro cytotoxicity was assessed against MCF-7, HepG-2, HCT-116, and normal WI-38 cells. Mechanistic assays included flow cytometry for cell cycle and apoptosis, and ELISA for caspase-3, Bcl-2, and Bax expression. Molecular docking, 200-ns molecular dynamics (MD) simulations, density functional theory (DFT) calculations, and in silico toxicity profiling supported experimental findings. RESULTS: Compound 11a exhibited the most potent and selective activity (IC₅₀: 9.49 µM for MCF-7, 12.89 µM for HepG-2; SI > 3). It induced >70% apoptosis and dual-phase (S and G2/M) cell cycle arrest. VEGFR-2 inhibition (IC₅₀ = 0.055 µM) was comparable to sorafenib. Computational studies confirmed stable binding at VEGFR-2 active sites. CONCLUSION: Compound 11a is a promising thiadiazole-based candidate with notable in vitro potency, selectivity, and mechanistic activity, supporting its potential for further pharmacokinetics/toxicity evaluation and structural refinement as a VEGFR-2-targeted agent.
VEGFR-2 inhibitorsthiadiazole derivativesanticancer drug discoveryapoptosis induction
mechanistic studies further confirmed the activation of the intrinsic apoptotic pathway, as evidenced by caspase-3 activation (8.2-fold), Bax upregulation (6.9-fold), and Bcl-2 downregulation (3.68-fold). Computational studies, including molecular docking and 200 ns molecular dynamics (MD) simulations, confirmed the stable interaction of 7a with VEGFR-2, showing binding affinities comparable to sorafenib. Further validation through MM-GBSA, ProLIF, PCAT, and FEL analyses reinforced its strong binding capability. Additionally, ADMET predictions suggested favorable pharmacokinetic properties, including good absorption, high plasma protein binding, and non-CYP2D6 inhibition. Moreover, toxicity analysis classified 7a as non-mutagenic and non-carcinogenic, with a lower predicted toxicity than sorafenib. Finally, density functional theory (DFT) calculations highlighted the structural stability and reactivity of 7a, further supporting its potential as a VEGFR-2 inhibitor. These findings suggest that 7a is a promising VEGFR-2 inhibitor with significant anticancer potential, favorable pharmacokinetics, and an improved safety profile. Further preclinical studies and structural modifications are warranted to optimize its therapeutic potential.
Breast cancer (BC) continues to be the most common cancer affecting women globally, posing significant therapeutic challenges due to limited therapeutic efficacy, non-specific drug targeting, systemic toxicity, and the emergence of chemoresistance. These hurdles emphasize the critical need for novel and effective treatment strategies. Nanomedicine has revolutionized cancer therapy, especially D-alpha-tocopheryl polyethylene glycol succinate (TPGS)-based nanoparticles (TPGS-NPs), which have emerged as a promising strategy due to their enhanced therapeutic potential. TPGS, an amphiphilic derivative of Vitamin E, not only enhances the solubility, stability, and bioavailability of lipophilic drugs but also exhibits intrinsic anti-BC properties. The incorporation of TPGS into NPs significantly enhances their physicochemical properties. Further, the engineering of TPGS-NPs with targeting ligands significantly improves their specificity towards cancer cells. Also, TPGS-NPs show great potential to improve photothermal and photodynamic therapies due to their excellent physicochemical properties. Moreover, TPGS-NPs demonstrate an excellent ability for gene (plasmid DNA, siRNA, and miRNA) delivery by enhancing stability and transfection efficiency. This review explores the multifaceted role of TPGS and the role of different TPGS-NPs in circumventing the limitations of conventional chemotherapy in BC treatment. Overall, developing TPGS-NPs offers a versatile and multifaceted approach to achieve better therapeutic outcomes against BC. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease.
breast cancertargeted drug deliveryphotothermal therapyphotodynamic therapy